François Virard, Stéphane Giraud, Mélanie Bonnet, Léa Magadoux, Laetitia Martin, et al.. Targeting ERK-MYD88 interaction leads to ERK dysregulation and immunogenic cancer cell death. Nature Communications, 2024, 15, pp.7037. ⟨10.1038/s41467-024-51275-z⟩. ⟨hal-04676566⟩

Beatrice Fervers, Olivia Pérol, Christine Lasset, Nora Moumjid, Pauline Vidican, et al.. An Integrated Cancer Prevention Strategy: the Viewpoint of the Leon Berard Comprehensive Cancer Center Lyon, France. Cancer Prevention Research, 2024, 17 (4), pp.133 - 140. ⟨10.1158/1940-6207.capr-23-0386⟩. ⟨hal-04646439⟩

Kévin Berthenet, Eliézer Aïmontché, Sara El Mrini, Johan Brière, Nathalie Pion, et al.. Spatial sequestration of activated-caspase 3 in aggresomes mediates resistance of neuroblastoma cell to bortezomib treatment. Scientific Reports, 2024, 14, ⟨10.1038/s41598-024-54140-7⟩. ⟨hal-04482149⟩

Armelle Dufresne, Valéry Attignon, Anthony Ferrari, Laurie Tonon, Sandrine Boyault, et al.. Added value of whole‐exome and RNA sequencing in advanced and refractory cancer patients with no molecular‐based treatment recommendation based on a 90‐gene panel. Cancer Medicine, 2024, 13 (7), pp.e7115. ⟨10.1002/cam4.7115⟩. ⟨hal-04646005⟩

Christian Pozzorini, Gregoire Andre, Tommaso Coletta, Adrien Buisson, Jonathan Bieler, et al.. GIInger predicts homologous recombination deficiency and patient response to PARPi treatment from shallow genomic profiles. Cell Reports Medicine, 2023, 4, ⟨10.1016/j.xcrm.2023.101344⟩. ⟨hal-04400735⟩

Amine Bouhamama, Benjamin Leporq, Khuram Faraz, Jean-Philippe Foy, Maxime Boussageon, et al.. Radiomics combined with transcriptomics to predict response to immunotherapy from patients treated with PD-1/PD-L1 inhibitors for advanced NSCLC. Frontiers in Radiology, 2023, 3, ⟨10.3389/fradi.2023.1168448⟩. ⟨hal-04209979⟩